ArticleFrontiers in medicine2026
Infants with retinopathy of prematurity (ROP) in Germany and Türkiye-a comparison based on data from the EU-ROP registry.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Data on regional differences in demographics and treatment patterns for treatment-warranted retinopathy of prematurity (ROP) is limited. In this study, data from the two countries with the highest patient numbers in the EU-ROP registry, Germany and Türkiye, are analyzed. Methods: The non-interventional, multicenter European ROP registry (EU-ROP) was established in 2021 to compare various parameters related to ROP. In this evaluation, 267 treated children (516 eyes) from Germany and 198 treated children (378 eyes) from Türkiye were included. The two cohorts were compared with regard to demographics, ROP treatment parameters and retreatment rates. Results: Infants in the German cohort had significantly lower gestational age (GA) as well as postmenstrual age (PMA) at initial treatment and (where applicable) at the time of retreatment. In the German cohort, the majority of eyes (56.1%) were treated due to stage 3 ROP in zone II with plus disease (II 3+). In the Turkish cohort, ROP II 3+ (22.0%), aggressive ROP (A-ROP) (17.9%), and ROP II 3- (17.3%) were the most common treatment indications. While ranibizumab was the predominant treatment modality in the German cohort (91.3%), about half of the eyes in the Turkish cohort were treated with laser coagulation (48.2%) while about 40% received intravitreal bevacizumab. Retreatment rates seemed to be comparable between Germany and Türkiye (28.1% vs. 27.3% of eyes) and were depending on the initial treatment method (30.5% after ranibizumab, 36.9% after bevacizumab, 14.2% after laser coagulation), although the retreatment indications [persistent avascular retina (PAR) vs. active ROP] appear to differ significantly between the two cohorts. Conclusion: In the investigated cohorts, ROP demographics, severity and treatment patterns differed significantly between Germany and Türkiye while the retreatment rate seems comparable. Different approaches to treatment of PAR may have contributed to the comparable retreatment rates despite the differences in initial treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.